{"id":"https://openalex.org/W3095300667","doi":"https://doi.org/10.1182/blood-2020-143005","title":"Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)","display_name":"Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)","publication_year":2020,"publication_date":"2020-11-05","ids":{"openalex":"https://openalex.org/W3095300667","doi":"https://doi.org/10.1182/blood-2020-143005","mag":"3095300667"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-143005","doi":"https://doi.org/10.1182/blood-2020-143005","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-143005","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040835019","display_name":"James R. Berenson","orcid":"https://orcid.org/0000-0003-1587-6104","observed_orcids":["https://orcid.org/0000-0003-1587-6104"]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James R. Berenson","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, CA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074344150","display_name":"Noemi Silagan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Noemi Silagan","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, CA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jennifer To","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer To","raw_affiliation_strings":["Oncotherapeutics Inc., West Hollywood,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics Inc., West Hollywood,","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068437316","display_name":"Tanya Magazinnik Spektor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tanya M. Spektor","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, CA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008684736","display_name":"Daisy Martinez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daisy Martinez","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, CA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Armando J. Sanchez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Armando J. Sanchez","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, CA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010805031","display_name":"Eli Forouzan","orcid":"https://orcid.org/0000-0002-5269-7394","observed_orcids":["https://orcid.org/0000-0002-5269-7394"]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eli Forouzan","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, CA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021554856","display_name":"Regina A. Swift","orcid":"https://orcid.org/0000-0002-0367-5965","observed_orcids":["https://orcid.org/0000-0002-0367-5965"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Regina Swift","raw_affiliation_strings":["James R. Berenson, MD, Inc., West Hollywood, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"James R. Berenson, MD, Inc., West Hollywood, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064758797","display_name":"Benjamin Eades","orcid":"https://orcid.org/0000-0002-4150-7786","observed_orcids":["https://orcid.org/0000-0002-4150-7786"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benjamin Eades","raw_affiliation_strings":["James Berenson MD, West Hollywood, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"James Berenson MD, West Hollywood, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006913373","display_name":"Gary K. Schwartz","orcid":"https://orcid.org/0000-0003-1813-5061","observed_orcids":["https://orcid.org/0000-0003-1813-5061"]},"institutions":[{"id":"https://openalex.org/I2801594134","display_name":"West Health","ror":"https://ror.org/056f7w112","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801594134"]},{"id":"https://openalex.org/I3025886734","display_name":"University of West Los Angeles","ror":"https://ror.org/045zwes19","country_code":"US","type":"education","lineage":["https://openalex.org/I3025886734"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary Schwartz","raw_affiliation_strings":["James R. Berenson, MD, Inc, West Hollywood,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"James R. Berenson, MD, Inc, West Hollywood,","institution_ids":["https://openalex.org/I2801594134","https://openalex.org/I3025886734"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031848378","display_name":"Shahrooz Eshaghian","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shahrooz Eshaghian","raw_affiliation_strings":["Compassionate Hematology & Oncology, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Compassionate Hematology & Oncology, Los Angeles, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112233517","display_name":"Ralph Vincent Boccia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210129209","display_name":"Center for Cancers and Blood Disorders","ror":"https://ror.org/03jh7ct92","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210129209"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ralph V. Boccia","raw_affiliation_strings":["Center for Cancer and Blood Disorders, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cancer and Blood Disorders, Bethesda, MD","institution_ids":["https://openalex.org/I4210129209"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021614746","display_name":"Honghao Yang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Honghao Hank Yang","raw_affiliation_strings":["Global Oncology, Alhambra, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Oncology, Alhambra, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111792159","display_name":"Stephen Wong Lim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Lim","raw_affiliation_strings":["Cedars-Sinai Medical Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Medical Center, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108763799","display_name":"Robert Allen Vescio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Vescio","raw_affiliation_strings":["Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"Supplement 1","first_page":"36","last_page":"36"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.921999990940094},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9909999966621399},{"id":"https://openalex.org/keywords/lenalidomide-resistance","display_name":"lenalidomide resistance","score":0.8399999737739563},{"id":"https://openalex.org/keywords/methylprednisolone","display_name":"methylprednisolone","score":0.8619999885559082},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.8679999709129333},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.7170000076293945},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.628000020980835},{"id":"https://openalex.org/keywords/mucin-1","display_name":"mucin 1","score":0.7979999780654907},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.843999981880188},{"id":"https://openalex.org/keywords/pd-l2","display_name":"PD-L2","score":0.8679999709129333},{"id":"https://openalex.org/keywords/m2-macrophage-polarization","display_name":"M2 macrophage polarization","score":0.9279999732971191},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6660000085830688},{"id":"https://openalex.org/keywords/clinical-benefit-rate","display_name":"clinical benefit rate","score":0.5249999761581421},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.9079999923706055},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.32499998807907104}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8180869817733765},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.7582196593284607},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.6096333265304565},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5986472368240356},{"id":"https://openalex.org/C2778524551","wikidata":"https://www.wikidata.org/wiki/Q7227206","display_name":"Pomalidomide","level":4,"score":0.49581846594810486},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4942812919616699},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4627954959869385},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.4599645733833313},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4467577636241913},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.4331797659397125},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.4123057723045349},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35470110177993774},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3294884264469147},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2977079749107361},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.27325043082237244},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-143005","doi":"https://doi.org/10.1182/blood-2020-143005","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-143005","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4200127932","https://openalex.org/W4251667674","https://openalex.org/W2914485485","https://openalex.org/W4291397341","https://openalex.org/W2999468559","https://openalex.org/W4310163207","https://openalex.org/W2954827306","https://openalex.org/W4394989363","https://openalex.org/W4389234657","https://openalex.org/W2912240505"],"abstract_inverted_index":{"Introduction":[0],"Ruxolitinib":[1,658],"(RUX)":[2],"is":[3,71,493,517],"an":[4,30,179],"FDA-approved":[5],"oral,":[6],"selective":[7],"inhibitor":[8,216,503],"of":[9,17,37,66,191,233,246,269,293,298,316,341,382,388,423,500,533,543],"Janus":[10],"kinase":[11],"(JAK)":[12],"1/2":[13],"for":[14,104,322,507,525,549,662],"the":[15,119,175,276,299,358,367,385,433,494,501],"treatment":[16,245,663],"patients":[18,110,154,192,201,302,308,361,398,410,428,444,452,478,664],"with":[19,50,194,224,363,462,505,514,540,547,665],"intermediate":[20],"or":[21,34,419],"high-risk":[22],"myelofibrosis":[23],"and":[24,59,77,80,83,114,124,130,141,147,150,164,171,209,217,237,286,306,332,349,365,369,374,396,402,436,448,465,469,474,484,521,659],"polycythemia":[25],"vera":[26],"who":[27,429],"have":[28,44,203,210,303,309],"had":[29,430,437],"inadequate":[31],"response":[32,143,288,389],"to":[33,73,128,157,186,213,275,351,413,440],"are":[35,537],"intolerant":[36],"hydroxyurea.":[38],"Preclinical":[39],"studies":[40,536],"from":[41,99,482],"our":[42],"laboratory":[43],"demonstrated":[45,117],"that":[46,118,512],"RUX":[47,63,125,163,227,364,504,513,544],"in":[48,57,60,90,174,545],"combination":[49,197,249,435,546],"dexamethasone":[51],"shows":[52,522],"marked":[53],"anti-myeloma":[54],"effects":[55],"both":[56],"vitro":[58],"vivo.":[61],"Specifically,":[62],"blocks":[64],"expression":[65,82],"Mucin":[67],"1":[68,102,313,449,491],"whose":[69],"function":[70],"linked":[72],"lenalidomide":[74],"(LEN)":[75],"resistance":[76],"down-regulates":[78],"PD-L1":[79],"PD-L2":[81],"reduces":[84],"tumor":[85],"stimulatory":[86],"M2":[87],"macrophage":[88],"polarization":[89],"multiple":[91],"myeloma":[92],"(MM)":[93],"bone":[94],"marrow.":[95],"Recently":[96],"published":[97],"results":[98,510],"a":[100,189,214,234,270,339,379],"Phase":[101,181],"trial":[103,183,492],"28":[105],"heavily":[106,527],"previously":[107,528],"treated":[108,193,221,362,529],"MM":[109,200,530],"administered":[111],"RUX,":[112],"LEN":[113,129,167,260,348,414,438],"methylprednisolone":[115],"(MP)":[116],"therapy":[120],"was":[121,184,250,258,273,327,390],"well":[122,519],"tolerated":[123,520],"overcame":[126],"refractoriness":[127],"steroids":[131,165,350,506,516,660],"(Berenson":[132],"et":[133],"al.,":[134],"Clin":[135],"Cancer":[136],"Res.":[137],"2020).":[138],"The":[139,244,324],"clinical":[140,169,282,498],"overall":[142,287],"rates":[144],"were":[145,155,220,280,320,335,354,371,411],"46%":[146],"28%,":[148],"respectively,":[149],"all":[151,355,407],"12":[152],"responding":[153,409],"refractory":[156,412],"LEN.":[158,218],"To":[159],"further":[160],"evaluate":[161],"whether":[162],"without":[166],"demonstrate":[168,511],"activity":[170,499],"its":[172],"tolerability":[173],"same":[176],"patient":[177,551],"population,":[178],"ongoing":[180,489],"I":[182],"expanded":[185],"also":[187,518],"include":[188],"cohort":[190],"this":[195,247,550],"two-drug":[196,248,434],"(NCT03110822).":[198],"Methods":[199],"must":[202],"failed":[204],">":[205],"3":[206,443],"prior":[207,345],"regimens":[208],"been":[211,304],"exposed":[212],"proteasome":[215],"Patients":[219,337],"orally":[222],"(PO)":[223],"15":[225,307,359],"mg":[226,239,263],"twice":[228],"daily":[229,265],"on":[230,266,418,432],"days":[231,267],"1-28":[232],"28-day":[235,271],"cycle":[236,272,315],"40":[238],"MP":[240,548],"every":[241],"other":[242],"day.":[243],"continued":[251],"until":[252],"disease":[253,401],"progression":[254],"(PD).":[255],"Once":[256],"PD":[257],"confirmed,":[259],"at":[261,311],"10":[262],"PO":[264],"1-21":[268],"added":[274,439],"regimen.":[277],"Primary":[278],"endpoints":[279],"safety,":[281],"benefit":[283],"rate":[284,289],"(CBR)":[285],"(ORR).":[290],"Results":[291],"As":[292],"July":[294],"25,":[295],"2020,":[296],"16":[297],"planned":[300],"29":[301],"enrolled,":[305],"completed":[310],"least":[312],"full":[314],"therapy;":[317],"and,":[318],"thus,":[319],"evaluable":[321,360],"efficacy.":[323],"median":[325,340,380,386],"age":[326],"64":[328],"years":[329],"(range,":[330,343,393],"46-77),":[331],"9":[333],"(60%)":[334],"male.":[336],"received":[338],"4":[342],"3-10)":[344],"treatments":[346],"including":[347,455],"which":[352],"they":[353],"refractory.":[356],"Of":[357,426],"steroids,":[366],"CBR":[368],"ORR":[370],"53%":[372],"(n=8)":[373],"33%":[375],"(n=5),":[376],"respectively.":[377,405],"With":[378],"follow-up":[381],"4.7":[383],"months,":[384],"duration":[387],"3.5":[391],"months":[392],"1-11+).":[394],"Five":[395],"2":[397],"showed":[399],"stable":[400],"progressive":[403,485],"disease,":[404],"Notably,":[406],"8":[408,421],"(i.e.":[415],"progressed":[416,431],"while":[417],"within":[420],"weeks":[422],"last":[424],"dosage).":[425],"6":[427],"their":[441],"regimen,":[442],"responded":[445],"(2":[446],"MR":[447],"PR).":[450],"Four":[451],"experienced":[453],"SAEs":[454],"sepsis":[456,461],"(7%),":[457,467,471,473],"group":[458],"B":[459],"strep":[460],"neutropenic":[463],"fever":[464],"nausea":[466],"pneumonia":[468,483],"pneumothorax":[470],"thrombocytopenia":[472],"hyperglycemia":[475],"(7%).":[476],"Two":[477],"died":[479],"(one":[480],"each":[481],"disease).":[486],"Conclusions":[487],"This":[488],"phase":[490],"first":[495],"study":[496],"reporting":[497],"JAK":[502],"MM.":[508],"These":[509],"only":[515,661],"promising":[523],"efficacy":[524],"treating":[526],"patients.":[531],"Because":[532],"this,":[534],"additional":[535],"being":[538],"conducted":[539],"higher":[541],"doses":[542],"population.":[552],"Disclosures":[553],"Berenson:":[554],"Takeda:":[555],"Consultancy,":[556,561,567,572,585,590,597,602,607,615,622,629,636,643,650],"Honoraria,":[557,562,568,573,577,586,591,598,603,608,616,623,630,637,644,651],"Speakers":[558,563,569,574,582,587,592,599,604,611,619,626,633,640,647,654],"Bureau;":[559,564,570,575,583,593,600,612,620,627,634,641,648],"Celgene:":[560],"Bristol-Myers":[565],"Squibb:":[566],"Janssen:":[571,642],"Incyte:":[576],"Patents":[578],"&":[579],"Royalties:":[580],"OncoTracker,":[581],"Amgen:":[584,621],"Bureau.":[588,605,655],"Swift:Jassen:":[589],"bristol":[594],"myers":[595],"squibb:":[596],"Amgent:":[601],"Boccia:Incyte:":[606],"Research":[609,617,624,631,638,645,652],"Funding,":[610,618,625,632,639,646,653],"Daiichi":[613],"Sankyo:":[614],"AstraZeneca:":[628],"Genentech:":[635],"Rigel:":[649],"OffLabel":[656],"Disclosure:":[657],"Multiple":[666],"Myeloma":[667]},"counts_by_year":[{"year":2022,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}